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Medicine in Colorectal Cancer
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Abstract
With estimated 700,000 deaths each year, colorectal carcinoma (CRC) continues 
to be the fourth leading cause of cancer-related deaths worldwide. Fortunately, the 
mortality of CRC is considered to be most avertable; hence, it is essential to develop 
new approaches for more accurate and early diagnosis of primary as well as meta-
static CRC, including genetic and biomarker tests. In this regard, the intercellular 
junctions and the insulin-like growth factor (IGF) axis attract increasing attention, 
since they are involved in several stages of cancer and for their vital role in regulating 
cell survival and growth; furthermore, constituents of intercellular junctions and of 
the IGF axis could be used as tumor and/or metastasis markers, which are becoming 
the focus of increasing research activities. Our experimental results highlight the 
importance of gene expression changes in the tight junction proteins claudins, and in 
the IGF-binding proteins IGFBP3 and IGFBP7. They show additionally that claudins 
and IGFBPs cannot be simply defined in terms of favoring or antagonizing cancer 
progression but have additional properties and activities, which become apparent 
only in the context of liver colonization. Furthermore, their intensive modulation 
during the initial phase of liver colonization may suggest them as early metastasis-
related markers.
Keywords: colorectal cancer, liver metastasis, personalized medicine, influence on 
treatment, claudins, IGFBPs, tumor cell reisolation, metastasis marker
1. Introduction
With estimated 700,000 deaths each year, colorectal carcinoma (CRC) contin-
ues to be the fourth leading cause of cancer-related deaths in both sexes world-
wide [1]. The 5-year relative survival rate for stage IV metastatic CRC is about 
11%, while in stage I this number rises to nearly 90%. These figures reflect the fact 
that despite the high incidence and mortality rate of CRC, its mortality is among 
the most avertable ones. In addition, the fact that liver metastasis is the cause 
of most deaths from CRC [2], underlines the significance of (early) metastasis 
prevention. In other words, it is of great importance to develop new approaches 
for more accurate and early diagnosis of primary CRC on one hand and of its 
metastasis on the other; including screening programs as well as genetic, molecu-
lar and biomarker tests.
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Colorectal cancer progression is driven by increasing or recurring growth of 
the primary carcinoma as well as hematogenic and lymphatic spread. For hemato-
genic spread, the liver is most important as it constitutes the first vascular bed in 
which disseminating CRC cells can be trapped after their dissemination. Hence, 
this organ is affected in up to 10–20% of CRC patients at the time of presentation. 
Another 20–25% will develop overt liver metastasis during the course of their 
illness [3, 4].
The main purpose of our experimental studies was first to develop a suitable 
model for investigating the efficacy of novel drugs [5–7]. One of the few well- 
characterized animal models for hepatic CRC benefits from the rat CC531 cell line. 
After injecting the cells, liver metastases develop and their growth has been fre-
quently used for studying effects of various anti-cancer treatments [8–10].
The second aim was to identify genes, which are instrumental in the survival 
and metastasis formation of disseminated CRC cells. In addition, we reasoned that 
there are genes, which are necessary for the primary tumor as well as those, which 
are essential for metastasis initiation and formation. We furthermore hypothesized 
that the latter genes would be modulated in expression during the cells’ colonization 
of the liver. Consequently, temporal changes in gene expression of CRC cells hom-
ing into the liver were investigated using an in vivo rat model, which is characterized 
by a definite metastatic proliferation-onset in rat liver after intra-portal inoculation 
of CC531 rat colorectal cancer cells. This model relies on the successful reisolation 
of CC531 cells at various time intervals after their injection into the mesenteric 
vein of syngeneic rats and allows exploring the chronological modulation of gene 
expression, from the very beginning of cancer cell homing into the liver to their 
final colonization of the whole organ. Based on this procedure, a cDNA microarray 
was performed to analyze gene expression profiles of several thousand genes in the 
reisolated CC531 cells. Upon analysis of microarray’s data, candidates from gene 
families being significantly up- or down-regulated were chosen for further study by 
using different in vitro models. These candidate genes included claudins and insulin 
like-growth factor binding proteins. It was hoped that the emerging genes or their 
products would be useful as target of a specific therapy or as a biomarker.
The National Institutes of Health defined a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention 
[11]. From a therapeutic point of view, genome variations are recognized as the 
main cause of variable response to and side effects of drugs and a “one size fits all” 
approach is not the best solution any more. The individual’s genetic and molecular 
makeup will be devoted to improve and develop more specific and “personal” 
diagnostic and therapeutic approaches.
Claudins (CLDNs) are tight junction (TJ) proteins that serve an intercellular 
adhesion function. The aberrant expression of individual claudins is well docu-
mented in different stages of various human cancers [12]. In addition, some clau-
dins were proven to be useful as biomarkers [13, 14].
The insulin-like growth factor (IGF) axis attracts increasing attention since it is 
involved in several stages of cancer [15–17], and for its vital role in regulating cell 
survival and growth [18, 19] as well as the possible use of constituents of this axis 
as tumor and/or metastasis markers, which is becoming the focus of increasing 
research activities.
The insulin-like growth factors IGF-I and –II orchestrate their roles through the 
interaction with other members in this system, namely their receptors IGF-IR and -IIR, 
their binding proteins (IGFBPs) and the IGFBP proteases including matrix metal-
loproteinases (MMPs), cathepsins, and kallikreins [20]. Type I receptor mediates the 
growth promoting effects of IGFs [21], which are further modulated by 6 binding 
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proteins (IGFBPs 1–6) with high affinity for IGFs [22] as well as at least 4 IGFBPs with 
low affinity [23, 24], also known as IGFBP-related proteins (IGFBP-rp-1-4).
Based on the observation that the increased expression of IGFBPs attenuates the 
proliferative and anti-apoptotic effects of IGFs, they have been long considered as 
tumor suppressors, mostly due to their IGF-dependent roles. Interestingly, however, 
in addition to these IGF-dependent actions, IGFBPs were found to exert IGF-
independent effects, as was reported for IGFBP1 [25], IGFBP3 [26–28], IGFBP5 
[29] and IGFBP7 (or IGFBP-rp1) [30–32].
In this report, we have used the technique of cancer cell reisolation from rat 
liver, which permitted to monitor for the first time the expression profile of numer-
ous candidate genes in a time-dependent manner. Based on these results we summa-
rize our knowledge on claudins and IGFBP members and delineate their potential as 
tumor and/or metastasis markers.
2. Results
2.1 Modulation of selected genes in reisolated CC531 tumor cells
For identifying genes, which enable tumor cells to metastasize and colonize the 
liver, the CC531 cells were reisolated from rats, which had been implanted intra-
portally with these tumor cells. After various periods following tumor cell implan-
tation, the CC531 cells were reisolated with a specific technique [33]. In subsequent 
experiments, these cells were used for mRNA and protein isolation and the mRNA 
screened by cDNA microarray and RT-PCR, and the proteins by Western blot.
As shown in Table 1, the microarray analysis revealed a significantly increased 
expression of insulin like growth factor binding proteins (Igfbp3 and Igfbp7) and 
significantly decreased expression levels of claudins (Cldn1 and Cldn4) in the 
beginning of liver colonization (days 3 and 6 after tumor implantation). These 
results were further confirmed by RT-PCR (for all four genes) and Western blot (for 
the two claudins and igfbp7) (Figure 1).
2.2 Effects of genes’ knockdown in colorectal cancer cells
To investigate the knockdown effect(s) of each gene on various functions of 
colorectal cancer cell lines, siRNA experiments for transient knockdown were 
performed.
Gene Time point of cell reisolation (days)a
3 6 9 14 21 14 (in vitro) 22 (in vitro)
Igfbp3 6.88b 13.62 6 18.03 17.29 1.56 0.9
Igfbp7 90.02 101.57 38.62 49.13 42.03 19.46 1.47
Cldn1 0.16 0.12 0.31 0.63 0.55 1.29 1.53
Cldn4 0.15 0.09 0.87 1.11 1.37 1.47 1.11
aThe day of tumor cell implantation was counted day 0.
bThe number denotes the fold change in expression versus an in vitro control.
Table 1. 
Gene expression profiles from members of two gene families, chosen from the microarray analysis of reisolated 
CC531 cells.
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Colorectal cancer cells (CC531, Caco2 or SW480) cultured in 6-well-plates were 
transfected with specific siRNA (200 nM) or negative control using Lipofectamine 
2000 (Invitrogen) following the manufacturer’s instructions. The cells were 
harvested at 24, 48 and 72 h after treatment.
As shown for overview in Table 2 (for details see Figures 2–4), knockdown 
of igfbp3 or igfbp7 was induced in cell lines with relevant expression only and 
caused significantly reduced proliferation rates (Figure 2A–C). Similarly, colony 
formation (Figure 3A–C) of CRC cells was diminished. Finally, cell migration was 
reduced in SW480 cells (Figure 4B), but not in CC531 (Figure 4A) and Caco2 
(Figure 4C) cells.
Interestingly, different effects were noticed after cldn1 or cldn4 knockdown in 
CC531 cells. No significant effect on cell proliferation was observed, while a significant 
inhibition of colony formation and significant stimulation of cell migration resulted 
from the siRNA knockdown of each claudin (Table 2).
Figure 1. 
Expression of Igfbp3, Igfbp7, cldn1, and cldn4 in reisolated CC531 cells. (A and C): Expression of Igfbp3 
and Igfbp7 (A) and of Cldn1 and Cldn4 (C) in reisolated CC531 cells as shown by RT-PCR compared to the 
expression of the housekeeping gene γ-tubulin. (B and D): Expression of the proteins IGFBP7 (B), CLDN1 and 
CLDN4 (D) in the reisolated CC531 cells as shown by western blot compared to the expression of ERK2 loading 
control. 1st lane: CC531 cells (control); 2nd, 3rd, 4th, 5th and 6th lanes: CC531 cells (reisolated from rat livers 
after 3, 6, 9, 14 and 21 days, respectively); 7th and 8th lanes: CC531 cells (reisolated after 21 days and cultured 
in vitro for further 14 and 22 days, respectively).
Target gene Cell proliferation Cell migration Colony formation
Igfbp3 (in SW480) ↓* ↓* ↓*
Igfbp7 (in CC531 or Caco2) ↓* ns ↓*
Cldn1 (in CC531) ns ↑* ↓*
Cldn4 (in CC531) ns ↑* ↓*
↓* and ↑* denote significant (p < 0.05) inhibition or stimulation of the investigated cell function (proliferation, 
migration or colony formation), respectively; ns denotes a nonsignificant effect.
Table 2. 
Overview of the siRNA knockdown effects of insulin like growth factor binding proteins 3 and 7 (Igfbp3 and 7) 
and claudins 1 and 4 (cldn1 and 4) on cellular functions (cell proliferation, migration and colony formation) 
of colorectal cancer cell lines (SW480, Caco2 and CC531).
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Figure 2. 
Effects of Igfbp7 or Igfbp3 knockdown on proliferation of colorectal cancer cells. (A) Reduced proliferation 
of rat CC531 colorectal cancer cells after si.Igfbp7 treatment. (B) Reduced proliferation of human SW480 
colorectal cancer cells after si.Igfbp3 treatment. (C) Reduced proliferation of human Caco2 colorectal 
cancer cells after si.Igfbp7 treatment. Data (n = 3) are shown as means ± S.D. in percentage of nonsense-
treated cells. Asterisk (*) denotes a significant difference to controls (p < 0.05). Abbreviations: CF; colony 
formation.
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Figure 3. 
Effects of Igfbp7 or Igfbp3 knockdown on colony formation of colorectal cancer cells. (A) Inhibited colony 
formation of rat CC531 colorectal cancer cells after si.Igfbp7 treatment. (B) Inhibited colony formation of 
human SW480 colorectal cancer cells after si.Igfbp3 treatment. (C) Inhibited colony formation of human 
Caco2 colorectal cancer cells after si.Igfbp7 treatment. Data (n = 3) are shown as means ± S.D. in percentage 
of nonsense-treated cells. Asterisk (*) denotes a significant difference to controls (p < 0.05). Abbreviations: CF; 
colony formation.
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Figure 4. 
Effects of Igfbp7 or Igfbp3 knockdown on migration of colorectal cancer cells. (A) Migration of rat CC531 
colorectal cancer cells after si.Igfbp7 treatment. (B) Reduced migration of human SW480 colorectal cancer cells 
after si.Igfbp3 treatment. (C) Migration of human Caco2 colorectal cancer cells after si.Igfbp7 treatment. Data 
(n = 3) are shown as means ± S.D. in percentage of nonsense-treated cells. Asterisk (*) denotes a significant 
difference to controls (p < 0.05). Abbreviations: CF; colony formation.
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3. Discussion
“If it were not for the great variability among individuals, medicine might as 
well be a science and not an art“ with these words the famous Canadian physi-
cian Sir William Osler anticipated and acknowledged the concept of personalized 
medicine since the nineteenth century.
Personalized medicine aims to optimize and tailor preventive and therapeutic 
approaches in favor of the best outcome for each patient, by using genetics, pro-
teomics, and biological information, including biomarkers [34]. It attempts to 
sub-categorize patients into different groups according to their “molecular make 
up”, i.e. using biomarkers.
Here we have used a rat model of liver metastasis to identify genes with importance 
for organ colonization, which could be used as biomarkers or therapeutic targets.
The selected model for this experiment is characterized by a defined metastatic 
proliferation-onset in rat liver after intra-portal inoculation of CC531 cancer cells. 
Consequently, this allows exploring the chronological modulation of gene expres-
sion, from the very beginning of cancer cell homing into the liver to their final 
colonization of the whole organ. The technique of cancer cell reisolation from rat 
liver permitted, for the first time, monitoring the expression profile of numerous 
candidate genes from the whole genome in a time-dependent manner.
The initial observation of these studies was based on cDNA microarray analysis 
of CC531 colon cancer cells, which allowed selecting candidates from gene families 
with significant up- or down-regulation. These candidates were further analyzed by 
different in vitro studies.
We have been focusing on the detection and evaluation of biomarkers for the 
last decades [33, 35–43]. From the several gene groups, which were highly modu-
lated in expression during liver colonization we focused on two families. Both were 
characterized by dramatic initial changes in expression, with claudins being down 
modulated and IGFBPs being up-regulated.
The first group (claudins; CLDNs) form the structural backbone of tight junctions 
(TJs), one type of cell-cell adhesion, and comprise at least 27 members of integral 
transmembrane proteins ranging in size from 20 to 34 kDa [12]. In recent years, the 
up- or down-modulated expression of several claudins has been associated with the 
progression of various cancers in humans, even in a tissue specific manner [12].
Interestingly, individual claudins are being used as therapeutic targets [44, 45] 
as well as diagnostic biomarkers [13, 14], making them a very interesting molecule 
to be investigated and characterized.
The second group of insulin like growth factor binding proteins (IGFBPs) 
differs in its importance from claudins, as they belong to the insulin-like growth 
factor (IGF) axis, which has a vital role in regulating cell survival and growth and is 
involved in several stages of cancer.
The expression of the two IGFBP genes, igfbp3 and igfbp7, was intensely upregu-
lated at the beginning of liver colonization (days 3 and 6 after tumor implantation). 
Subsequently, however, this increased expression returned gradually to normal, 
hence we assume that the up-regulation of IGFBPs is essential for dissemination and 
homing of tumor cells into the liver during early metastasis formation. This strongly 
suggests that the tumor/metastasis microenvironment has a crucial impact on the 
regulation of igfbp3 and igfbp7. Furthermore, these results along with previous 
studies [28, 46–48] show that the balanced expression of IGFBP3 and IGFBP7 is 
very essential for several cellular functions as both, up- and down-regulation of 
these two genes were related to malignant properties. This further suggests that the 
aberrant expression of these two genes can be an early indicator of CRC progression.
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Further verification of their value arises from studies that demonstrate involve-
ment of the IGF axis in several stages of cancer and for its vital role in regulating 
cell and tissue survival, growth and differentiation [18, 19]. In addition, the possible 
use of constituents of this axis as tumor and/or metastasis markers is becoming 
the focus of increasing research activities [49–51]. Most in vitro studies, reported a 
tumor suppressor function of IGFBP3 and IGFBP7 through IGF-dependent and/or 
independent mechanisms [27, 31, 52, 53]. At variance to these studies, our experi-
ments on silencing IGFBP3 and IGFBP7 in three CRC cell lines uniformly show 
reduced proliferation, colony formation, and for IGFBP3, also reduced migration. 
Our observations are in agreement with few reports, which related IGFBP3 and 
IGFBP7 to growth promoting functions [28, 54]. Accordingly, these and our results 
support the idea that IGFBP3 and IGFBP7 are multi-functional.
IGFBP3 is well known in the literature: It is the predominant IGFBP in plasma, 
hence plays a crucial role in regulating the bioavailability of plasma IGFs, and it is 
expressed locally in most tissues including the intestine [55]. Additionally, IGFBP3 
induces apoptosis and inhibits proliferation in human colon [56], prostate [57], breast 
[58], and lung cancer cells [26] in vitro and in experimental CRC animal models [59]. 
Furthermore, wild type p53 can induce IGFBP3 expression [60], thus enhancing the 
p53-dependent apoptotic response of CRC cells to DNA damage [56]. Reduced levels 
of IGFBP3 and elevated circulating levels of IGF-I were associated with increased risk 
of prostate [61], breast [62], and colorectal [63, 64] cancers. Nevertheless, this associa-
tion was not confirmed in all conducted studies [65–67]. It was observed that TGF-β 
can induce IGFBP3 and mediates its proliferative response in aggressive CRC cells, 
which exempts the studies reporting a tumor suppressor function of IGFBP3 [28].
In contrast to IGFBP3, the regulation and functions of IGFBP7 are less investigated. 
This gene was originally cloned as a gene, which is down-regulated in meningioma 
cell lines [68]. IGFBP7 is usually expressed by colonic mucosa [65], however both, 
up- and down-regulation patterns were recorded in the context of cancer [46, 47]. 
Lately, it was shown that IGFBP7 is a direct p53 target and the DNA methylation 
mediated-epigenetic silencing of IGFBP7 was associated with the absence of p53 
mutations in CRC [30]. Until now, in vitro experiments demonstrated a negative effect 
of IGFBP7 on the growth of various cancer cells, including cervical carcinoma (HeLa) 
[69], osteosarcoma (Saos-2) [69], and breast [70]. Furthermore, in human CRC cell 
lines, expression of IGFBP7 was detectable in Caco2 and SW480 cells only, whereas 
its expression in invading tumor cells associated with poor prognosis in CRC patients 
[71]. In addition, immunohistochemistry and RT-PCR showed IGFBP7 over-expres-
sion in CRC tissues as compared to the respective normal tissues [36].
As also known from the literature, several members of the IGF axis were found 
to be prognostic markers for various tumor types, including IGFBP5 and IGFBP7 
for nonsmall cell lung cancer (NSCLC) [72], IGFBP2 and IGFBP3 as compensatory 
biomarkers for CA19-9 in early-stage pancreatic cancer [51], IGF-1 for metastatic 
uveal melanoma [49] and IGF-IR for glioblastoma [50]. In addition, a recent study 
showed that certain single nucleotide polymorphisms (SNPs) in IGF1R and IGF2R 
were associated (positively or inversely, respectively) with adenomas in Caucasian, 
but not in African American CRC patients [73]. Similarly, specific SNPs in the IGF-l 
gene were suggested as risk assessment markers of gastrointestinal cancers [74]. 
All these studies emphasize the crucial role of the patient’s genetic background in 
tailoring the therapeutic approach to fit the “size” of this particular patient.
With regard to using the above family members as prognostic marker, the past 
experience should be considered. Contrasting with our expectations and reports 
from the literature, no significant correlation was found between the increased 
expression levels of four known tumor progression-associated genes (Opn, Tgf-β, 
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Mmp-2 and Cox-2) and the prognostic value of these genes in CRC patients [43]. 
This raises an important to answer question, i.e. what would be the best procedure 
to apply personalized medicine effectively and reliably? Could it be a minimum 
number of (bio)-markers for each cancer type to be tested, or should it be a complex 
approach as high throughput genome sequencing, as it is increasingly performed?
Ideally, a few markers would be better suited regarding costs of analysis and 
time until a patient can benefit from the results. However, there are currently 
only few markers which succeeded to be applied accordingly. Therefore, even 
more methods are being approached to assess the specific changes inherent to the 
full genome.
4. Conclusion and perspectives
Here we show a new high throughput approach in exploring genes relevant to 
CRC progression in terms of liver metastasis. Our method has yielded initial results 
related to the importance of claudins and IGFBP in liver colonization. Nevertheless, 
we reason that other genes, which result from this model, might be even more 
valuable. For instance, one of the very important and interesting gene families that 
resulted from this model, which is extensively investigated, is the endothelin system 
with all its components (endothelins, their converting enzymes and their receptors). 
Several members of this system could prove useful as tumor/metastasis markers. 
Future experiments will show whether such a functional model can compete or com-
plement, at least partially, other techniques, including whole genome sequencing.
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